Halozyme Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0J2O.L | REGN | URGN | TLT.V | BIIB | LFCR | |
|---|---|---|---|---|---|---|
| Market cap | — | 84.33B | 1.72B | 68.31M | 37.51B | 241.46M |
| P/E (TTM) | 41.5 | 20.3 | — | — | 45.1 | — |
| Forward P/E | — | 13.0 | 13.6 | -22.0 | 15.4 | -8.2 |
| Price/book | 98.8 | 2.6 | -13.0 | 9.6 | 2.0 | -7.0 |
| Dividend yield | — | 0.47% | — | — | — | — |
| 1-year change | +15.67% | +39.95% | +104.73% | −9.52% | +60.57% | −6.46% |
| Today | +1.05% | +1.67% | −0.93% | +15.79% | +5.34% | 0.00% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0J2O.L news ›Halozyme Therapeutics Wins Injunction Barring Manufacture, Sale of Merck's Keytruda SC in Multiple EU Markets
... Merck & Co., Inc. Halozyme Therapeutics Wins Injunction Barring Manufacture, Sale of Merck's Keytruda SC in Multiple EU Markets Published on 10/07/2026 at 08:48 am EDT Latest news about Merck & Co., Inc. Chart Merck & Co., Inc. Income…
[Form 3] HALOZYME THERAPEUTICS, INC. Initial Statement of Beneficial Ownership
Halozyme Therapeutics (HALO) is a San Diego-based biopharmaceutical company focused on ENHANZE and Hypercon drug delivery technologies for subcutaneous biologics. - [Form 3] HALOZYME THERAPEUTICS, INC. Initial Statement of Beneficial…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net2
-
marketscreener.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.